

## ASX Release

---

# Anagrelide Cancer Patent For Australia

- **Anagrelide, an FDA and EMA approved drug to treat blood disorders, is being repurposed for use in cancer**
- **The Australian Patent Office has accepted and will now grant a patent for this new use of anagrelide**

**PERTH, AUSTRALIA – 08 September 2020:** SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, is pleased to announce that the Australian Patent Office has now accepted the patent application and the patent will proceed to grant.

The Australian Patent Office will grant SUDA's Application No. 2015370666 titled "Prevention and Treatment of Metastatic Disease in Thrombocytotic Cancer Patients". The patent has an expiry date of December 2035. SUDA already holds a granted patent for Europe and earlier this year received a grant for the patent in Japan.

SUDA is developing anagrelide for the treatment of metastatic disease in patients who have certain solid tumour cancers, with the intention of increasing progression-free survival or lifespan. Recent research has demonstrated the proactive role that platelets play in facilitating the growth and spread of cancer, in addition to suppressing immune responses to cancer. It has also been shown that cancer cells can trigger a negative feedback loop, sending out chemicals to signal to the body to produce more platelets and hence aid the further development of cancer.

Solid tumour types for which increased platelet levels have been reported to occur in a significant proportion of the patient population include melanoma, mesothelioma, ovarian, vulvar, cervical, renal cell, lung, glioblastoma, pancreatic, endometrial and colorectal cancer.

Anagrelide not only advantageously lowers blood platelets but it has also been shown to inhibit cancer cell movement towards platelet-producing cells, megakaryocytes, principally found in the bone marrow but also the lung, two likely sites of metastases.

Additionally, SUDA recently completed a pharmacokinetic study at Covance Inc. in the UK. The preliminary data supported the Company's hypothesis that an oral spray of the drug may be a safer way to deliver anagrelide to treat metastatic disease in patients with solid tumour cancers, as it may reduce the unwanted cardiovascular side effects associated with the current commercial capsule formulation.

SUDA's CEO Dr Michael Baker commented: "We are very pleased to add Australia to the list of territories for which we have a granted patent for this new use of anagrelide, the

other territories being Europe and Japan. In drug development, patents are an important part of the value creation process and this grant in Australia strengthens our ability to maximise value from the anagrelide program”.

For and on behalf of the Board and for further information please contact:

**Dr Michael Baker**

**Managing Director and Chief Executive Officer**

**SUDA Pharmaceuticals Ltd**

Tel +61 (0) 403 468 187

mbaker@sudapharma.com

#### **NOTES TO EDITORS:**

##### **About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA’s product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem tartrate for the treatment of short-term insomnia. ZolpiMist is approved by the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of migraine headache, motion sickness, drug resistant epilepsy and certain cancers.

For more information, visit [www.sudapharma.com](http://www.sudapharma.com)